Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients

Kumi Ishida, Takuya Inoue, Kaori Fujiwara, Taisuke Sakanaka, Ken Narabayashi, Sadaharu Nouda, Toshihiko Okada, Kazuki Kakimoto, Takanori Kuramoto, Ken Kawakami, Yosuke Abe, Toshihisa Takeuchi, Mitsuyuki Murano, Satoshi Tokioka, Eiji Umegaki, Kazuhide Higuchi

Kumi Ishida, Takuya Inoue, Kaori Fujiwara, Taisuke Sakanaka, Ken Narabayashi, Sadaharu Nouda, Toshihiko Okada, Kazuki Kakimoto, Takanori Kuramoto, Ken Kawakami, Yosuke Abe, Toshihisa Takeuchi, Mitsuyuki Murano, Satoshi Tokioka, Eiji Umegaki, Kazuhide Higuchi, the Second Department of Internal Medicine, Osaka Medical College, Takatsuki City, Osaka 569-8686, Japan

Author contributions: Ishida K and Inoue T performed data compilation, analysis, statistical analysis and manuscript preparation; Fujiwara K, Sakanaka T, Narabayashi K, Nouda S, Okada T, Kakimoto K, Kuramoto T, Kawakami K, and Abe Y has performed the adalimumab/adalimumab + azathioprine treatment; Takeuchi T, Murano M, Tokioka S, and Umegaki E assisted in the analysis and interpretation of data; Higuchi K and Umegaki E revised this manuscript.

Correspondence to: Takuya Inoue, MD, PhD, the Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigakumachi, Takatsuki City, Osaka 569-8686, Japan. ureuretakuwan@yahoo.co.jp

Telephone: +81-72-6831221 Fax: +81-72-6846532
Received: December 20, 2012 Revised: January 17, 2013
Accepted: February 8, 2013 Published online: May 7, 2013

Abstract

AIM: To assess adalimumab’s efficacy with concomitant azathioprine (AZA) for induction and maintenance of clinical remission in Japanese Crohn’s disease (CD) patients.

METHODS: This retrospective, observational, single-center study enrolled 28 consecutive CD patients treated with adalimumab (ADA). Mean age and mean disease duration were 38.1 ± 11.8 years and 11.8 ± 10.1 years, respectively. The baseline mean Crohn’s disease activity index (CDAI) and C-reactive protein were 177.8 ± 82.0 and 0.70 ± 0.83 mg/dL, respectively. Twelve of these patients also received a concomitant stable dose of AZA. ADA was subcutaneously administered: 160 mg at week 0, 80 mg at week 2, followed by 40 mg every other week. Clinical response and remission rates were assessed via CDAI and C-reactive protein for 24 wk.

RESULTS: The mean CDAI at weeks 2, 4, 8, and 24 was 124.4, 120.2, 123.6, and 135.1, respectively. The CDAI was significantly decreased at weeks 2 and 4 with ADA and was significantly suppressed at 24 wk with ADA/AZA. Overall clinical remission rates at weeks 4 and 24 were 66.7% and 63.2%, respectively. Although no statistically significant difference in C-reactive protein was demonstrated, ADA with AZA resulted in a greater statistically significant improvement in CDAI at 24 wk, compared to ADA alone.

CONCLUSION: Scheduled ADA with concomitant AZA may be more effective for clinical remission achievement at 24 wk in Japanese Crohn’s disease patients.

Key words: Crohn’s disease; Adalimumab; Immunomodulator; Azathioprine; Inflammatory bowel disease

Core tip: In this study, the authors found that adalimumab (ADA) treatment with concomitant azathioprine usage significantly suppressed the Crohn’s disease activity index and increased the remission rate at 24 wk after the initiation of therapy, compared with ADA treatment alone.
INTRODUCTION

Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine implicated in the pathogenesis of inflammatory bowel disease (IBD). Thus far, a variety of therapeutic approaches have been used to inhibit TNF-α in patients with IBD, including infliximab (IFX), which was the first biologic agent approved for the treatment of IBD. IFX is a mouse and human chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against TNF-α; it binds to both the soluble and transmembrane forms of TNF-α and is effective as both an induction and maintenance therapy in patients with Crohn’s disease (CD), including patients who have draining fistulas. However, IFX has a 25% murine fraction that has potent immunogenicity and can cause the formation of human anti-chimeric antibodies (HACA). Furthermore, this potent immunogenicity may lead to the loss of efficacy, hypersensitivity reactions, or infusion reactions.

Adalimumab (ADA) is the second biologic agent approved for use in the treatment of IBD. It is a subcutaneously administered, recombinant, fully human, IgG1 monoclonal antibody that binds with a high affinity and specificity to TNF-α and was found to be effective in refractory CD patients who were either naive to or previously treated with IFX. Combination therapy with IFX and an immunosuppressant demonstrated increased efficacy compared with nonconcomitant use of immunosuppressants. Nonetheless, limited data are available for ADA. In the pivotal registration study of ADA (Crohn’s trial of the fully Human antibody ADA for Remission Maintenance, CHARM), post-hoc analysis did not detect an impact of coadministration of immunosuppressants on the remission rates achieved at 1 year. Adizzzone et al. reported that ADA with concomitant immunosuppressant treatment was not associated with the loss of response or the need for dose escalation. However, Reenaers et al. reported that there may be a benefit from using immunosuppressive drugs during the first semester of initiating ADA treatment, with a slight decrease in ADA failure and lower need for ADA dosage escalation.

In Japan, ADA was approved for the treatment of CD; however, only limited data have been collected on its optimal usage. Therefore, this study aimed to assess the impact of ADA with concomitant azathioprine (AZA) therapy on the rate of clinical remission during maintenance with ADA in CD patients at the Osaka Medical College Hospital during routine clinical practice.

MATERIALS AND METHODS

Study participants

Between November 2010 and March 2012, about 28 CD patients who were diagnosed by clinical, endoscopic, and histological criteria and who received ADA at the Osaka Medical College Hospital, Osaka, Japan, were consecutively enrolled in this retrospective, observational, single-center study. The patients were informed about the potential risks and benefits of ADA therapy and were provided and signed informed consent forms before all procedures. The medical records of all participating patients were reviewed by two senior investigators (Ishida K and Inoue T) for the following information: demographics; disease duration; disease location; prior surgical history; perianal disease presence; smoking behavior; previous IFX treatment and response to IFX treatment; Crohn’s disease activity index (CDAI); C-reactive protein (CRP) levels; and concomitant medications (corticosteroids, AZA, mesalazine, and elemental diet).

All patients received 160 mg of ADA subcutaneously at week 0, 80 mg at week 2, followed by 40 mg every other week. A clinical response was defined as a ΔCDAI > 70 points, whereas a clinical remission was defined as a CDAI < 150 points. The loss of response to IFX was defined as a loss of therapeutic efficacy after > 2 IFX infusions.

Statistical analysis

Categorical data were compared by the χ² test or the Fisher’s exact test, and continuous variables were compared by the Student t test. The results were expressed as the mean ± SD. P values less than 0.05 were considered to be statistically significant. All calculations were made using the StatView system (SAS Institute, Cary, NC, United States).

RESULTS

Patient characteristics

ADA was administered to 28 consecutive patients with CD from November 2011 to March 2012 at the Osaka Medical College Hospital (male-to-female ratio: 22/6; age at presentation: 38.1 ± 11.8 years; and disease duration: 11.8 ± 10.1 years). The patients’ baseline characteristics and demographics are listed in Table 1. According to the Montreal classification, patients presented with CD in the following locations: about 10.7% (3/28) in an isolated ileal location; 17.9% (5/28) in an isolated colonic location; and 71.4% (20/28) in an ileocolonic location. Of the patients, 60.7% (17/28) had a history of previous IFX treatment and response to IFX treatment; 57.1% had perianal disease, and 17.9% had an associated fistulizing disease. Two patients (7.1%) were current smokers.

Seventeen (60.7%) patients had previously taken IFX, and 8 patients did not have a response to IFX, including no primary response in one patient and emergent allergic reaction in another patient. Twelve of the 28 patients were treated with ADA and a concomitant stable dose of AZA throughout the observational period. The mean CDAI and mean CRP at baseline were 177.8 ± 82.0 and 0.70 ± 0.83 mg/dL, respectively.
Clinical efficacy of ADA therapy

The overall clinical response and remission rates are shown in Table 2. The rates of clinical remission at weeks 2, 4, 8, and 24 were 60.0%, 66.7%, 69.6%, and 63.2%, respectively. The mean CDAI of all patients at weeks 2, 4, 8, and 24 was 124.4 ± 60.2, 120.0 ± 66.8, 123.6 ± 73.5, and 135.1 ± 74.4, respectively. The CDAI was significantly decreased commencing 2 wk after the initiation of ADA treatment and remained low for 24 wk (Table 2).

Impact of ADA/AZA on the clinical remission compared to ADA maintenance

Regarding the concomitant use of immunosuppressive agents, 12 patients (42.9%) were treated with a stable dose of AZA (50.0 ± 21.3 mg/d, 1.0 ± 0.5 mg/kg/d) before the initiation of ADA. The concomitant use of AZA was well tolerated, with only minor side effects. Although there were no statistically significant differences seen until 12 wk into ADA and AZA treatment (compared with ADA treatment), combinational therapy with ADA and AZA significantly increased the clinical remission rate (Figure 1) and reduced the CDAI, compared with nonconcomitant use at week 24 (Figure 2A).

Sixteen of the 28 patients were found to have increased CRP serum levels (> 0.25 mg/dL) before starting ADA therapy. The mean serum CRP of all of the patients at weeks 2, 4, 8, and 24 was 0.27 ± 0.40, 0.28 ± 0.51, 0.46 ± 0.69, and 0.51 ± 0.94 mg/dL, respectively. ADA significantly reduced the CRP levels at weeks 2 and 4 after the initiation of treatment. The concomitant use of AZA tended to maintain low CRP levels for 24 wk, even though the result was not statistically significant (CRP levels at weeks 0 and 24 were 0.66 ± 0.73 and 0.27 ± 0.44 mg/dL, respectively; P = 0.09, Figure 2B).

DISCUSSION

The effectiveness of AZA in CD patients treated with IFX has been clearly reported by many investigators. However, few reports have demonstrated the benefits of ADA and AZA combination therapy. In this study, we analyzed the use of ADA and AZA in patients with mild to moderate CD at our clinical practice and found that scheduled ADA with concomitant use of AZA was more effective in inducing and maintaining remission for 24 wk after the initiation of ADA treatment, compared with ADA monotherapy. Although ADA monotherapy was also able to induce and maintain clinical remission from 2 to 24 wk compared to the baseline, the effects of the combination therapy were better. Since previous IFX nonresponse and previous treatment with an anti-TNF-α agent were reported to be associated with a decreased clinical efficacy and a loss of response,[20] we also compared the CDAI between anti-TNF-naïve patients and anti-TNF-treated patients in this study, but there was no significant difference.

ADA is a human monoclonal IgG1 antibody that has demonstrated efficacy in the induction and maintenance of clinical remission in patients with moderate to severe CD and is useful in patients who have lost responsiveness to IFX.[11-15]. IFX, a chimeric anti-TNF-α antibody, has potent immunogenicity; repeated administration of IFX could result in the development of antibodies that may lead to the loss of response.[21] Although no consensus has yet been established on the appropriateness of concomitant immunomodulators with anti-TNF-α antibody therapy for CD,[22-24] immunosuppressants were shown to inhibit the development of HACA[19]. Moreover, since the clearance of IFX is affected by the presence of HACA, IFX serum levels were significantly less frequently observed in patients with combined immunosuppressants.[22] IFX could result in the development of HACA in patients with IBD and reported that IBD flare-ups, perianal complications, and switching to ADA were reported to be associated with a decreased clinical efficacy and a loss of response.[20] We also compared the CDAI between anti-TNF-naïve patients and anti-TNF-treated patients in this study, but there was no significant difference.

ADA significantly reduced the CRP levels at weeks 2 and 4 after the initiation of treatment. The concomitant use of AZA tended to maintain low CRP levels for 24 wk, even though the result was not statistically significant (CRP levels at weeks 0 and 24 were 0.66 ± 0.73 and 0.27 ± 0.44 mg/dL, respectively; P = 0.09, Figure 2B).

Table 1 Baseline characteristics of all patients who received adalimumab for treatment of Crohn’s disease n (%)  

|                 | Adalimumab | Combination | Total   |
|-----------------|------------|-------------|---------|
| Gender          | n = 16     | n = 12      | n = 28  |
| Male            | 13 (81.3)  | 9 (75.0)    | 22 (78.6) |
| Female          | 3 (18.7)   | 3 (25.0)    | 6 (21.4)  |
| Age at presentation (yr) | 43.1 ± 11.8 | 31.4 ± 8.3 | 38.1 ± 11.8 |
| Disease duration (yr) | 13.6 ± 11.5 | 9.3 ± 7.6 | 11.8 ± 10.1 |
| Location of disease |           |             |         |
| Isolated ileal  | 2 (12.5)   | 1 (8.3)     | 3 (10.7)  |
| Isolated colonic| 4 (25.0)   | 1 (8.3)     | 5 (17.9)  |
| Leocolonic      | 10 (62.5)  | 10 (83.3)   | 20 (71.4) |
| Previous resection | 10 (62.5)  | 7 (58.3)    | 17 (60.7) |
| Perianal disease | 10 (62.5)  | 6 (50)      | 16 (57.1) |
| Current smokers | 1 (6.3)    | 1 (8.3)     | 2 (7.1)   |
| Previous anti-infliximab treatment | 10 (62.5) | 7 (58.3) | 17 (60.7) |
| Primary nonresponse | 0 (0.0)   | 1 (8.3)     | 1 (3.6)   |
| Secondary loss of response | 8 (50.0)  | 6 (50.0)    | 14 (50.0) |
| Allergic reaction | 1 (6.3)    | 0 (0.0)     | 1 (3.6)   |
| Others          | 1 (6.3)    | 0 (0.0)     | 1 (3.6)   |
| CDAI at initiation of adalimumab therapy | 195.4 ± 89.2 | 152.2 ± 65.8 | 177.8 ± 82.0 |
| CDAI > 150 at initiation of adalimumab therapy | 9 | 7 | 16 |
| CRP at initiation of adalimumab therapy | 0.72 ± 0.92 | 0.66 ± 0.73 | 0.70 ± 0.83 |

1 Data are expressed as mean ± SD. CDAI: Crohn’s disease activity index.

**P** < 0.05 vs adalimumab.
studies, combined with anti-ADA antibody and ADA trough level measurements, are required [19]. In this study, we found that ADA treatment with concomitant AZA usage significantly suppressed the CDAI and increased the remission rate at 24 weeks after the initiation of therapy, compared with ADA treatment alone. Furthermore, these results were not consistent with previous reports showing that the efficacy of ADA is independent of the use of concomitant immunosuppressive therapy with IFX and AZA during the first semester of initiating ADA demonstrated a slight decrease in ADA failure and a lower need for ADA dose escalation. Moreover, the presence of anti-ADA antibodies and a low serum ADA concentration have been reported to be associated with a diminished clinical response in rheumatoid arthritis patients, and the concomitant use of an immunomodulator significantly suppressed the concentration of anti-ADA antibodies [27-29]. Interestingly, in this study, AZA in the presence of ADA provides better efficacy in patients it has previously failed. However, some patients with IFX had not early received concomitant AZA. Therefore, we consider that ADA and AZA combination therapy may be more effective than ADA monotherapy via the inhibition of the development of anti-ADA antibodies. Prospective studies, combined with anti-ADA antibody and ADA trough level measurements, are required [19]. In this study, we found that ADA treatment with concomitant AZA usage significantly suppressed the CDAI and increased the remission rate at 24 weeks after the initiation of therapy, compared with ADA treatment alone. Furthermore, these results were not consistent with previous reports showing that the efficacy of ADA is independent of the use of concomitant immunosuppressive therapy.

Table 2  Clinical efficacy of adalimumab therapy

| Week | 0   | 2   | 4   | 8   | 24  |
|------|-----|-----|-----|-----|-----|
| n    | 27  | 25  | 24  | 23  | 19  |
| CDAI | 177.8 ± 82.0 | 124.4 ± 60.2 a | 120.0 ± 66.8 b | 123.6 ± 73.5 c | 135.1 ± 74.4 c |
| Remission | 37% | 60% | 66.70% | 69.60% | 63.20% |

Remission: Crohn’s disease activity index (CDAI) < 150 points. *P < 0.05 vs week 0.

that combination therapy with IFX and AZA may have an added benefit in maintaining the remission of CD. With regard to ADA, a substantial proportion of patients, including previously treated anti-TNF-α patients and anti-TNF-α treatment-naïve patients, needed dose escalation during ADA treatment [11,24]. However, concomitant immunosuppressive therapy was not associated with a loss of response or a need for dose escalation and did not influence the development of ADA antibodies [27-29].

Recently, Reenaers et al [19] reported that usage of ADA with immunosuppressive drugs, such as AZA, during the first semester of initiating ADA demonstrated a slight decrease in ADA failure and a lower need for ADA dose escalation. Moreover, the presence of anti-ADA antibodies and a low serum ADA concentration have been reported to be associated with a diminished clinical response in rheumatoid arthritis patients, and the concomitant use of an immunomodulator significantly suppressed the concentration of anti-ADA antibodies [27-29]. Interestingly, in this study, AZA in the presence of ADA provides better efficacy in patients it has previously failed. However, some patients with IFX had not early received concomitant AZA. Therefore, we consider that ADA and AZA combination therapy may be more effective than ADA monotherapy via the inhibition of the development of anti-ADA antibodies. Prospective studies, combined with anti-ADA antibody and ADA trough level measurements, are required [19].

In this study, we found that ADA treatment with concomitant AZA usage significantly suppressed the CDAI and increased the remission rate at 24 weeks after the initiation of therapy, compared with ADA treatment alone. Furthermore, these results were not consistent with previous reports showing that the efficacy of ADA is independent of the use of concomitant immunosuppressive therapy.

Figure 1  Clinical remission rate. Combinational therapy with adalimumab and azathioprine significantly increased the clinical remission rate vs nonconcomitant use at week 24.

Figure 2  Mean Crohn’s disease activity index and C-reactive protein through week 24. A: Combinational therapy with adalimumab (ADA) and azathioprine (AZA) significantly reduced the Crohn’s disease activity index (CDAI), compared with nonconcomitant use at week 24. *P < 0.05 vs week 0; **P < 0.05 vs adalimumab; B: The concomitant use of AZA tended to maintain low C-reactive protein (CRP) levels for 24 wk (CRP levels at weeks 0 and 24 were 0.66 ± 0.73 and 0.27 ± 0.44, respectively, P = 0.09).
The benefits of azathioprine (AZA) in Crohn’s disease (CD) with infliximab as scheduled anti-tumor necrosis factor-α maintenance therapy have been established but remain unclear with adalimumab (ADA).

**Research frontiers**

So far, there have been few reports demonstrating that CD patients could achieve better clinical remission with ADA and immunomodulator combination therapy, compared with ADA monotherapy.

**Innovations and breakthroughs**

This is the first study reported in Asia on the effect of ADA with concomitant AZA for induction and maintenance of clinical remission in CD patients. The results of this study showed that ADA treatment with concomitant AZA usage significantly suppressed the Crohn’s disease activity index and increased the remission rate at 24 wk after the initiation of therapy, compared with ADA treatment alone.

**Applications**

Although further long-term studies evaluating the efficacy of combination therapy with ADA and AZA are required, this study suggests that ADA with concomitant AZA therapy may provide clinical benefit in inducing long-term remission. The results of this study may help physicians decide whether to use combination therapy.

**Peer review**

This is an interesting small retrospective, observational, study assessing the effect of effects of ADA treatment with concomitant AZA in CD patients.

**REFERENCES**

1. Van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut 1997; 40: 443-448 [PMID: 9176068 DOI: 10.1136/gut.51.3.362]
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429 [PMID:12167685]
3. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclós B. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 1996; 39: 684-689 [PMID: 9026483 DOI:10.1136/gut.39.5.684]
4. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-1608 [PMID:12016425 DOI: 10.1053/gast.2002.33426]
5. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts P. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035 [PMID: 9291530 DOI:10.1056/NEJM1997090337010]
6. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962 DOI: 10.1016/S0140-6736(02)08512-4]
7. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398-1405 [PMID: 10228190 DOI: 10.1056/NEJM199905063401804]
8. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876-885 [PMID: 14985485 DOI: 10.1056/NEJMoa030815]
9. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2: 542-553 [PMID: 15224278 DOI: 10.1016/
Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries.
and regional differences. J Dig Dis 2010; 11: 134-147 [PMID: 20579217 DOI: 10.1111/j.1751-2980.2010.00429.x]

35 Zheng CQ, Hu GZ, Zeng ZS, Lin LJ, Gu GG. Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning. World J Gastroenterol 2003; 9: 1646-1656 [PMID: 12918095]

36 Sugimura M, Kinouchi Y, Takahashi S, Aihara H, Takagi S, Negoro K, Obana N, Kojima Y, Matsumoto K, Kikuchi T, Hiroki M, Oomori S, Shimosegawa T. CARD15/NOD2 mutational analysis in Japanese patients with Crohn’s disease. Clin Genet 2003; 63: 160-162 [PMID: 12630966 DOI: 10.1046/j.0009-9163.2002.00174.x]

37 Martín-de-Carpi J, Pociello N, Varea V. Long-term efficacy of adalimumab in paediatric Crohn’s disease patients naïve to other anti-TNF therapies. J Crohns Colitis 2010; 4: 594-598 [PMID: 21122566 DOI: 10.1016/j.crohns.2010.04.002]